Your browser doesn't support javascript.
loading
Baricitinib for the treatment of rheumatoid arthritis.
Urits, Ivan; Israel, Jacob; Hakobyan, Hayk; Yusin, George; Lassiter, Grace; Fackler, Nathan; Berger, Amnon A; Kassem, Hisham; Kaye, Alan; Viswanath, Omar.
Afiliación
  • Urits I; Department of Anesthesiology, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States.
  • Israel J; Georgetown University School of Medicine, Washington, District of Columbia, United States.
  • Hakobyan H; Georgetown University School of Medicine, Washington, District of Columbia, United States.
  • Yusin G; Georgetown University School of Medicine, Washington, District of Columbia, United States.
  • Lassiter G; Georgetown University School of Medicine, Washington, District of Columbia, United States.
  • Fackler N; Georgetown University School of Medicine, Washington, District of Columbia, United States.
  • Berger AA; Department of Anesthesiology, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States.
  • Kassem H; Department of Anesthesiology, Mount Sinai Medical Center, Miami Beach, Florida, United States.
  • Kaye A; Department of Anesthesiology, Louisiana State University Health Shreveport, Shreveport, Los Angeles, United States.
  • Viswanath O; Valley Anesthesiology and Pain Consultants - Envision Physician Services, Phoenix, Arizona, United States.
Reumatologia ; 58(6): 407-415, 2020.
Article en En | MEDLINE | ID: mdl-33456084
Rheumatoid arthritis (RA) is a common inflammatory disease with several implications on health, disability and economy. Conventional treatment for RA centers on anti-inflammatory drugs and specific targeting of tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6). Baricitinib is a novel, Food and Drug Administration (FDA) approved, once daily oral drug that is effective in combination with current treatment and results in significantly reduced symptoms with good safety profile. Further studies are required to find rare side effects and evaluate the long term efficacy in disease modulation and patient symptom reduction. This is a comprehensive review of the literature on baricitinib for the treatment of RA. This review provides an update on the pathophysiology, diagnosis and conventional treatment of RA, then proceeds to introduce baricitinib and the data that exists to support or refute its use in RA. The presented study also indicated clinical trials confirming the effectiveness of baricitinib in this indication.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Reumatologia Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Polonia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Reumatologia Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Polonia